In this exclusive UroStream interview, we had the privilege of speaking with Dr. Thomas Powles, MD, a leading oncologist at Barts Health NHS Trust and the global lead investigator of the EV-302 trial, during his recent visit to Beijing.
Dr. Powles offers valuable insights into the clinical impact of enfortumab vedotin plus pembrolizumab in metastatic urothelial cancer, explores the expanding role of antibody-drug conjugates (ADCs), and reflects on how this combination may reshape future treatment strategies including the potential to move away from cystectomy in selected patients.
